Rifaximin (brand name Xifaxan) is one of the prescription options sometimes used for irritable bowel syndrome with diarrhea (IBS-D). For many people, IBS-D symptoms come and go, and treatment decisions often focus on finding an option that improves daily comfort while fitting real life (work, school, travel, meals, and stress). This article shares education-only information about rifaximin IBS-D, including who it tends to help, what a typical course looks like, and common questions to bring to a clinician.
Who rifaximin may help (and why an antibiotic is used for IBS-D)
Rifaximin is a gut-focused antibiotic that is Food and Drug Administration (FDA) approved for IBS-D in adults. It is different from many “antibiotics for IBS” that are absorbed throughout the body, because rifaximin is designed to work mainly inside the intestines. In IBS-D, the goal is not to treat an infection in the usual sense. Instead, rifaximin is thought to help some people by shifting gut bacteria and related gut chemistry in a way that reduces IBS-D symptoms. Professional guidelines from the American College of Gastroenterology support rifaximin to treat overall (global) IBS-D symptoms, based on clinical trial evidence. [1]
In the major TARGET clinical trials, adults with IBS without constipation took rifaximin for two weeks and were then followed for about 10 weeks. A larger share of people taking rifaximin reported adequate relief of overall IBS symptoms compared with placebo, and bloating relief also improved in more people taking rifaximin. [2]
Rifaximin is one of several IBS-D meds, so it often comes up when symptoms are disruptive (frequent loose stools, urgency, belly pain, bloating), and a clinician has confirmed the symptoms fit IBS-D rather than another condition that needs a different plan.
What to expect from a course, possible side effects, and common questions
A standard IBS-D regimen is rifaximin 550 mg by mouth three times a day for 14 days (a short course, not a daily long-term maintenance prescription). If symptoms improve and later return, the FDA label notes that retreatment can be done up to two times with the same regimen. [3] The American Gastroenterological Association similarly suggests rifaximin for IBS-D and suggests retreatment for people who respond and later have symptoms come back. [4]
Rifaximin side effects are often mild, but they still matter when weighing options. In IBS-D studies summarized in the FDA prescribing information, the most common side effects included nausea and increased liver enzymes (ALT). The prescribing information also warns that diarrhea from Clostridioides difficile can occur with antibiotics and should be considered if diarrhea happens after therapy or worsens during therapy. [3] MedlinePlus also lists possible side effects (such as nausea, stomach pain, dizziness, and tiredness) and notes that watery or bloody diarrhea with cramps and fever can occur during treatment or for up to two months afterward, which is one reason clinicians may ask patients to report concerning symptoms promptly. [5]
Helpful questions to ask a clinician when discussing xifaxan IBS-D include:
- “What symptoms should improve first (diarrhea, urgency, pain, bloating), and how will response be measured?”
- “If symptoms return, what would a rifaximin repeat course plan look like, and when would it be considered?”
- “Are there reasons rifaximin may be a poor fit (other conditions, liver disease history, medication interactions)?”
Primary CTA: Track response to treatment in Aidy by logging stool changes, urgency, abdominal pain, bloating, and days missed from normal activities, so patterns are easier to review at follow-ups.